OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

The All-In podcast episode dives deep into the current state of AI, starting with OpenAI's missed user and revenue targets, sparking debate over whether this signals strategic failure or a temporary misalignment due to massive compute commitments. Despite the setbacks, the hosts argue that OpenAI is gaining ground in enterprise and coding applications, particularly with the release of GPT-5.5 and its cyber capabilities, while Anthropic faces challenges from compute constraints. The Elon vs. Sam Altman trial is framed as a pivotal legal battle over OpenAI’s nonprofit origins, with leaked diary entries from Greg Brockman adding dramatic tension. Meanwhile, the hyperscalers—Amazon, Microsoft, Google, and Meta—are making unprecedented $725 billion in CapEx commitments, fueling a new infrastructure boom reminiscent of the dot-com era, but with real demand driving investment. The episode also explores the rise of AI agents, warning of risks like the 'Claude ate homework' incident, and emphasizes the need for supervision. Finally, the conversation turns to the revolutionary peptide drug Retatrutide, showing dramatic weight loss and metabolic benefits, with potential to become a 'de-aging' therapy, and a personal anecdote from David Friedberg about attending a Supreme Court hearing, highlighting the institution’s enduring reverence.